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Abstract
We hypothesized that lymph node involvement in minor salivary gland cancers is
associated with clinical and pathological factors commonly available to the
clinician after a typical initial workup. Our aim was to identify these factors using
a dataset that allowed us to compile the largest series of minor salivary gland
cancers in the published literature. Using this dataset we also aimed to
characterize the distribution of histological types by primary site, identify the
predictors of the use of external beam radiation therapy and neck dissection, and
examine the effect of lymph node involvement on survival. Using the SEER
database, we identified 2667 minor salivary gland cancers with known lymph
node status from 1988 to 2004. Univariate and multivariate analyses were
conducted to identify factors associated with the use of neck dissection, the use
of external beam radiation therapy, and the presence of cervical lymph node
metastases. Kaplan Meier survival curves were constructed to examine the effect
of lymph node involvement on survival. 426 (16.0%) patients had neck nodal
involvement. Factors associated with neck nodal involvement on univariate
analysis included increasing age, male gender, increasing tumor size, high tumor
grade, T3-T4 stage, adenocarcinoma or mucoepidermoid carcinomas, and
pharyngeal site of primary malignancy. On multivariate analysis, four statistically
significant factors were identified, which included male gender, T3-T4 stage,
pharyngeal site of primary malignancy, and high-grade adenocarcinoma or highgrade mucoepidermoid carcinomas. The proportions (and 95% confidence
intervals) of patients with lymph node involvement for those with 0, 1, 2, 3 and 4
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of these prognostic factors were 0.02 (0.01-0.03), 0.09 (0.07-0.11), 0.17 (0.140.21), 0.41 (0.33-0.49), and 0.70 (0.54-0.85) respectively. Grade was a
significant predictor of metastasis for adenocarcinoma and mucoepidermoid
carcinoma but not for adenoid cystic carcinoma. Overall survival was significantly
worse at 5, 10, and 15 years for patients with lymph node involvement on
presentation. A prognostic index using the four clinicopathological factors listed
above can effectively differentiate patients into risk groups of nodal metastasis.
The precision of this index is subject to the limitations of SEER data and it should
be validated in further clinical studies.
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Introduction
Minor salivary gland cancers represent a rare group of epithelial
malignancies. The most common site is the hard palate, but tumors can also
arise throughout the oral cavity, as well as the pharynx, larynx, nasal cavity and
paranasal sinuses. Tumors of the minor salivary glands are two to three times
more likely to be malignant than parotid and submandibular gland tumors.1-3
Overall, 25% of salivary gland cancers arise in minor salivary glands. These
glands account for approximately five percent of saliva production.
Metastasis of most minor salivary gland neoplasms typically occurs by
lymphatic spread via the cervical lymph nodes. Cervical lymph node involvement
is associated with decreased survival in both major4-10 and minor salivary gland
cancers.11, 12 Anderson and colleagues analyzed 95 patients diagnosed and
treated at the University of Alabama at Birmingham over a 35-year period.11 In
multivariate analysis, three factors were predictive of increased disease-free
survival at four years. These were stage I or II cancer, negative surgical margins,
and the absence of cervical lymph node metastasis. These results emphasize
the need for early detection—in order to treat the patient before they reach
advanced stage—and the desirability of treating of cervical lymph nodes when
they are present.
Clinically positive lymph nodes are removed by surgical neck dissection
often accompanied by neck irradiation. Patients believed to be likely to harbor
occult nodal metastasis are treated with an elective neck dissection and/or neck
irradiation. Clear, evidence-based guidelines that demonstrate which patients will
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present with lymph node metastasis are currently lacking in the literature,
although it is known that certain histological types such as adenoid cystic and
acinic cell carcinomas are associated with less risk of neck metastasis.5, 13
The factors that influence the occurrence of lymph node metastasis in the
much more common squamous cell carcinoma of the upper aerodigestive tract
have been reported. Woolgar and colleagues investigated the relationship
between cervical lymph node metastasis and certain clinical and pathologic
factors in 45 patients with tongue or floor of mouth tumors who received neck
dissection.14 They found no relationship between lymph node metastasis and
gender, age, primary site, TNM stage, or T stage. There was a significant
relationship with the tumor surface dimension and two measures of tumor
thickness. This study was limited by a small sample size.
Tumor size and grade of malignancy were shown to predict for the risk of
nodal metastasis in univariate analysis by Rodriguez-Cuevas and colleagues.15
This study included 150 salivary gland tumors, of which only 18 were located in
the minor salivary glands. Major gland cancers involved the cervical lymph nodes
in 25/132 (18.9%) of cases and minor gland cancers involved the cervical lymph
nodes in 4/18 (22%) of cases. Undifferentiated and squamous cell carcinomas
(major glands only) had the highest rate of clinical node metastasis: 10/32 (31%).
An intermediate group consisted of papillary carcinomas, involving the lymph
nodes in 2 of 12 cases (17%), adenoid cystic carcinoma, involving the lymph
nodes in 5 of 28 cases (17%), and mucoepidermoid carcinomas, involving the
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lymph nodes in 9 of 48 cases (18%). The incidence in acinic cell carcinomas was
only 1 in 14 (7%).
Terhaard and colleagues analyzed 565 malignant salivary gland tumors
(157 in the minor salivary glands) from the Dutch Head and Neck Oncology
Cooperative Group in 2004 for independent prognostic factors for locoregional
control.13 Eighty-nine percent were treated with curative intent. In multivariate
analysis, local control was associated with clinical T stage, bone invasion, site,
resection margin, and treatment. Regional control was associated with N stage,
facial nerve paralysis, and treatment. There was a 9.7 relative risk for local
recurrence with surgery alone, compared with surgery plus postoperative
radiotherapy and a 2.3 relative risk for regional recurrence. Surgery alone was
completed in 20% of the patients and surgery combined with radiation therapy
was completed in 68% of the patients. Despite an imbalance of other prognostic
factors favoring the surgery only group, the combined group had much lower
rates of locoregional recurrence.
In a study looking only at 145 surgically treated parotid carcinomas, Regis
de Brito Santos found, in multivariate analysis, histological type
(adenocarcinoma, undifferentiated carcinoma, high grade mucoepidermoid
carcinoma, squamous cell carcinoma, and salivary duct carcinoma) (p < 0.001),
T3 or T4 stage (p = 0.03), and severe desmoplasia (p = 0.006) to be
independently associated with lymph node metastasis.16 In an analysis of the
SEER database, Bhattacharyya and Fried examined the predictors of lymph
node metastasis also in parotid carcinomas drawing on 1268 cases from 1988 to
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1998. They concluded that facial nerve involvement, tumor grade, and squamous
cell carcinoma subtype were the most important factors contributing to lymph
node metastasis.17
The evidence above is the best available for the identification of clinical
and pathological associated with lymph node metastasis in minor salivary gland
cancers. Unfortunately, most of the studies deal mostly with major salivary gland
cancers or squamous cell carcinomas of the upper aerodigestive tract.
This study attempts to answer the question for minor salivary gland
cancers using the National Cancer Institute’s Surveillance, Epidemiology and
End Results (SEER) database. The SEER database is a collection of cancer
registries that has historically included 14% of the U.S. population. As more
registries have been added over the years, that percentage has grown to
approximately 25%.

Statement of Purpose, Specific Hypothesis, and Specific Aims of the
Thesis
We used the SEER database to compile the largest, population-based
dataset of malignant minor salivary gland cancers yet reported. We describe
demographic, clinical and pathological characteristics of these tumors including
the distribution of histological type by the site of the primary malignancy. We
hypothesized that some patient and tumor characteristics commonly known by a
clinician faced with the decision to treat the cervical lymph nodes may help define
risk classes for lymph node involvement. We examined these associations with
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cervical lymph node metastasis both by univariate analysis and while controlling
for other variables. A simple prognostic index was derived to predict the
presence of lymph node metastasis using the four most important
clinicopathological factors. We also analyze the clinicopathological
characteristics associated with treatment with external beam radiation therapy
and surgical neck dissection. Finally, we examined the survival of patients with
lymph node metastasis versus those without.

Methods
All procedures and analysis outlined in the following section were
conduced by Shane Lloyd, the thesis candidate. Exemption from IRB review was
obtained for this study as the study does not involve human subjects and the
data is on a freely available public database.
We queried the National Cancer Institute’s SEER registries database to
select minor salivary gland malignancies from 1988 to 2004. Minor salivary gland
malignancies were defined by primary site and histological criteria as follows.
Primary site criteria included cancers of the oral cavity, pharynx, nasal cavity,
and larynx. The oral cavity included the lips (C00.0-C00.9), tongue (C020-C023,
C028-C029), gingiva (C030-C039, C062), floor of mouth (C040-049), hard palate
(C050), and buccal mucosa (C060-C061). The pharynx included the base of
tongue (C019), tonsils (C024), soft palate (C051-C052), and all other pharyngeal
sites (C090-C139). The larynx included all laryngeal sites (C320-C329). Finally,
the nasal cavity was grouped with the nasal cavity itself (C300), the middle ear
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(C301) and paranasal sinuses (C310-C319). Pathologic criteria included the
salivary gland malignancies described in the World Health Organization
International Histological Classification of Tumors.18 Seventy-four cases were
excluded from analysis because they were not the patient’s first known head and
neck malignancy. Excluding these cases ensures that the source of nodal
metastasis is the primary cancer in question. To present a complete populationbased survey of the distribution of histological types in the various primary sites,
we included patients whether or not their lymph node status was known. In all
subsequent analyses, 1259 cases with unknown or unrecorded lymph node
status were excluded leaving a final dataset of 2667 patients. Complete patient
characteristics are presented for this final set of patients.
All staging information including lymph node involvement represents the
information available on the initial workup or upon the completion of the first
primary directed surgery or surgeries. Disease progression known to have
occurred after the original date of diagnosis is not included. As the SEER
program does not record T stage before 2004, we used information recorded in
the SEER program on tumor size and extension19 to assign T stage as defined
by the AJCC Cancer Staging Manual, 6th edition, 2002. This method resulted in T
stage assignment that was identical to that found in SEER’s derived AJCC T
stage variable that is available only for 2004.
Clinical and pathological factors potentially associated with neck lymph
node metastasis were identified and included patient gender, age, race
(Caucasian, African American, or other), site of primary malignancy, tumor grade,
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tumor size, T stage, and year of diagnosis. Grade information was grouped into
low-grade (well differentiated to moderately differentiated) and high-grade (poorly
differentiated or undifferentiated/anaplastic) categories. All variables were
examined individually using the Pearson double-sided chi square test for their
effect on lymph node involvement. Statistically significant factors were then
included in a multivariate logistic regression model. Because more extensive
nodal sampling or neck dissection may lead to a higher probability of finding
positive lymph nodes, we included an independent variable for the number of
nodes examined. Interactions between explanatory variables were also
considered. We searched for interaction terms by forcing entry of all variables
individually and allowing entry of interaction terms in forward stepwise fashion
with a likelihood ratio significance cutoff of 0.05. Finally, the four most significant
factors were combined into a categorical variable of 16 groups representing all
possible permutations of the presence or absence of these four factors. This
categorical variable was then re-entered in the logistic regression with the same
covariate controls. Groups with similar odds ratios were combined in order to
construct an index predictive of the presence or absence of lymph node
involvement in minor salivary gland cancers. This index was then validated using
10-fold cross-validation.
Generally, we omitted cases from our logistic regressions if input variables
were missing. This reduces the power and has the potential to introduce bias into
our analysis. As a safeguard against this, we used maximum likelihood
estimation to impute the missing data in our regression of clinicopathological
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factors on lymph node involvement. This is a statistical way of making a best
guess at missing variables—such as stage or tumor size—based on the known
characteristics of each case with a missing variable. We imputed the data five
times and the estimated values were combined to arrive at beta and standard
deviation estimates that take advantage of all the data. This was done to affirm
the independent statistical significance of each of the variables included in the
index. Only known information and no imputed information was used in
constructing the index or in other analyses in this study.
The clinicopathological variables listed above were also examined for their
association with neck dissection and external beam radiation by logistic
regression. A neck dissection was defined as any case with four or more lymph
nodes examined by a pathologist. The Hosmer-Lemeshow goodness-of-fit
statistic was used to evaluate regression outputs. Patients with distant
metastasis were excluded from multivariate analyses of lymph node metastasis
and survival analysis. A receiver operator curve was generated for the prognostic
index of lymph node involvement in minor salivary gland cancer.
Finally, we generated Kaplan-Meier survival curves for patients with and
without lymph node metastasis respectively.
Univariate analysis, multivariate logistic regression, Hosmer-Lemeshow
tests, receiver operator curves, and Kaplan-Meier survival curves were computed
using SPSS version 16 (SPSS Inc., Chicago, IL). Cross-validation was computed
using the R programming language with the Zelig package.20 Multiple imputation
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of missing data was conducted using the R programming language with the Zelig
and AmeliaView21 packages.

Results
Table 1: Location of 4616 Cases of Minor Salivary Gland Cancer by
Histological Type.

Oral Cavity (%)

Pharynx and
Tonsils (%)

Nasal Cavity,
Sinuses,
Middle Ear (%)

Larynx (%)

Total (%)

Adenocarcinoma

654 (29.9)

350 (38.9)

280 (41.4)

100 (62.1)

1384 (35.3)

Mucoepidermoid Carcinoma

991 (45.3)

262 (29.1)

62 (9.2)

18 (11.2)

1333 (34.0)

Adenoid Cystic Carcinoma

436 (19.9)

249 (27.7)

307 (45.4)

30 (18.6)

1022 (26.0)

Acinic Cell Carcinoma

60 (2.7)

14 (1.6)

7 (1.0)

Miscellaneous Carcinoma

48 (2.2)

25 (2.8)

20 (3.0)

13 (8.1)

2189 (55.8)

900 (22.9)

676 (17.2)

161 (4.1)

Total (% of Total in Site)

0 -

81 (2.1)
106 (2.7)
3926

Percentages in parentheses represent the percentage of cancers in the site that
are the histological type in question. Percentages in the bottom row represent the
percentage of the total found in that site.
The distribution of histological type by primary tumor site is listed in Table
1. Patient and tumor characteristics and the results of univariate analysis of the
effects of each clinical or pathologic factor individually on lymph node metastasis
are shown in Table 2. Overall, lymph node metastasis was found in 426 (16.0%)
of cases. In patients who underwent surgery and were staged by pathology,
54.2% had lymph node metastasis. In patients who were staged clinically, 8.8%
had lymph node metastasis.
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Table 2. Patient Characteristics and Clinical and Pathologic Factors and
Their Effect on Nodal Involvement in Univariate Analysis.

Baseline Characteristic
Gender
Female
Male
Race
Caucasian
African American
Other
Histological Type
Adenoid Cystic Carcinoma
Acinic Cell Carcinoma
Mucoepidermoid Carcinoma
Adenocarcinoma
Miscellaneous Carcinoma
Grade
Low-Grade
High-Grade
Primary Site
Mouth
Pharynx Including Tonsil
Nasal Cavity, Sinuses, Middle Ear
Larynx
T Stage
T1
T2
T3
T4
Neck Dissection (> 3 Nodes Examined)
Yes
No
EBRT
Yes
No

Age
Year of Diagnosis
Tumor Size (mm)
Number of Nodes Examined

Total No. (%)

Incident Nodal
Involvement (%)

1423 (53.4)
1244 (46.4)

11.4
21.2

2101
324
216

(79.6)
(12.3)
(8.2)

15.6
20.4
13.4

695
41
929
929
73

(26.1)
(1.5)
(34.8)
(34.8)
(2.7)

10.2
2.4
15.8
21.3
12.3

1299
461

(73.8)
(26.2)

8.5
39.9

P-Value*
< 0.001

0.052

< 0.001

< 0.001

< 0.001
1493
667
397
110

(56.0)
(25.0)
(14.9)
(4.1)

9.7
32.5
6.8
33.6

945
401
190
514

(44.1)
(18.7)
(8.9)
(24.0)

6.1
20.4
20.5
21.6

391
2257

(14.8)
(85.2)

54.2
8.8

1125
1466

(43.4)
(56.6)

28.5
6.2
LNs
No LNs
Involved Involved
Mean
Mean
(SE)
(SE)
57.7 (0.4) 60.9 (0.7)
1999
1998
24.6 (0.7) 32.9 (1.1)
1.4 (0.1) 15.7 (1.1)

< 0.001

< 0.001

< 0.001

Total No.
2667
2667
1828
2667

< 0.001
0.005
< 0.001
< 0.001

*Pearson Chi square test double-sided p-value. SE: Standard Error.
The T stage is unknown for 92 patients who had distant metastasis because
distant metastasis overrides tumor extension data in SEER coding. LN = Lymph
Node.
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To arrive at a model that illustrates the relative importance of factors
commonly available to physicians considering neck dissection and/or neck
irradiation, we included clinical and pathological factors found to be significant on
univariate analysis in a multivariate logistic regression on lymph node
involvement (Table 3). An interaction was found between grade and histology
such that adenocarcinomas and mucoepidermoid carcinomas were more likely to
present with lymph node metastasis when they were high-grade. However, grade
had no effect on nodal involvement for other histological types or sub-types. We
therefore considered low- and high-grade malignancies separately for
adenocarcinomas and mucoepidermoid carcinomas but not for the other
histological types.
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Table 3: Multivariate Logistic Regression of Clinicopathological Factors on
Regional Nodal Metastasis.
Variable (Comparison Group for Categorical
variables)

Odds Ratio (95%
Confidence Interval)

P-Value

Histological Type and Grade
(v. Adenoid Cystic Carcinoma)
Acinic Cell Carcinoma

< 0.001 ***
0

†

Mucoepidermoid Carcinoma, Low-Grade

1.06 (0.56-2.02)

Mucoepidermoid Carcinoma, High-Grade

4.04 (2.09-7.80)

< 0.001 ***

Adenocarcinoma, Low-Grade

1.91 (1.04-3.51)

0.037 *

Adenocarcinoma, High-Grade

6.72 (3.48-13.00)

< 0.001 ***

Miscellaneous

1.73 (0.40-7.44)

Primary Site (v. Mouth)

0.858

0.461
< 0.001 ***

Pharynx Including Tonsil

3.54 (2.27-5.54)

Nasal Cavity, Sinuses, and Middle Ear

0.71 (0.30-1.69)

0.443

Larynx

1.55 (0.55-4.40)

0.407

T Stage (v. T1)

< 0.001 ***

0.030 *

T2

1.68 (0.95-2.97)

0.074

T3

2.57 (1.19-5.55)

0.017 *

T4

2.25 (1.26-4.04)

0.006 **

Male Sex (v. Female)

2.16 (1.42-3.30)

< 0.001 ***

Tumor Size (mm)

1.00 (0.99-1.01)

0.947

Age

1.01 (1.00-1.02)

0.161

Race (v. Caucasian)

0.268

African American

1.61 (0.91-2.87)

0.105

Other

1.08 (0.49-2.36)

0.852

0.99 (0.95-1.04)

0.698

Controls
Year of Diagnosis
Number of Nodes Examined (v. None)

< 0.001 ***

1-3

5.43 (2.69-10.97)

< 0.001 ***

>3

24.01 (14.99-38.46)

< 0.001 ***

1533 patients are included in this analysis. The p-value is listed for the odds ratio
of each variable and for the Wald statistic for inclusion of complete categorical
variable groups. Cases with distant metastasis are excluded from this analysis
because T stage was not recorded/unknown when there was distant metastasis.
The Hosmer-Lemeshow test for this regression had a p-value of 0.023. The
NagelKerke R Square is 0.526. ***p < 0.001. **0.001 < p <= 0.010. *0.010 < p <=
0.050. †The number of lymph node positive cases is too small for analysis.
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Controlling for all factors listed, male gender, pharyngeal primary site, T3
or T4 stage, and high-grade adenocarcinoma or high-grade mucoepidermoid
carcinoma are statistically significant predictors of regional nodal metastasis.
When these four variables were combined into a single categorical variable of 16
groups representing all possible permutations of their presence or absence, they
resulted in the odds ratios listed in Table 4. Groups based loosely on these odds
ratios were delineated which corresponded with the number, zero through four, of
the four variables present. Because of this, a predictive index for lymph node
involvement is proposed based on the number present of the following four
factors: male gender, pharyngeal primary site, T3 or T4 stage, and high-grade
adenocarcinoma or mucoepidermoid carcinoma (Table 5). The area under the
receiver operator curve (95% CI) using this index was = 0.757 (0.724-0.790). If
one uses a positive test cutoff of one factor present, the sensitivity and specificity
were 95.4% and 28.4%. Using two factors as the positive test cutoff results in a
sensitivity and specificity of 66.9% and 72.2%, using three factors results in a
sensitivity and specificity of 35.6% and 94.0%, and using all four factors results in
a sensitivity and specificity of 10.0% and 99.4%. When the predictive capability of
the logistic regression model which uses the number of factors present examined
using 10-fold cross validation, the average squared prediction error was 0.0923
indicating accurate prediction of the presence or absence of lymph node
involvement when dividing the data into training and validating sets differently 10
times.
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Table 4: Odds Ratios of Combinations of the Presence or Absence of Four
Factors.
Lymph Node Positive
Cases
Lymph
Proportion (95%
Node
Confidence
Positive
Interval)

Variable
All Factors Absent

Logistic Regression

Odds Ratio (95%
Confidence Interval)

P-Value

9 /457

0.02 (0.01-0.03)

Male

17/326

0.05 (0.03-0.08)

2.18 (0.92-5.19)

0.078

T3-4

22/219

0.10 (0.06-0.14)

3.77 (1.62-8.77)

0.002

Pharynx

18/163

0.11 (0.06-0.16)

3.99 (1.65-9.62)

0.001

8 /45

0.18 (0.07-0.30)

5.562 (1.79-17.33)

0.003

Male and T3-4

19/191

0.10 (0.06-0.14)

3.69 (1.55-8.81)

0.003

Male and Pharynx

15/99

0.15 (0.08-0.22)

6.08 (2.38-15.55)

< 0.001

T3-4 and High-Grade ADC or MEC

6 /31

0.19 (0.05-0.33)

6.64 (1.88-23.52)

< 0.001

T3-4 and Pharynx

7 /35

0.20 (0.07-0.33)

6.94 (2.12-22.76)

0.001

Male and High-Grade ADC or MEC

15/41

0.37 (0.22-0.51)

11.70 (4.14-33.07)

< 0.001

Pharynx and High-Grade ADC or MEC

10/20

0.50 (0.28-0.72)

16.29 (4.58-57.92)

< 0.001

All but Pharynx

20/60

0.33 (0.21-0.45)

17.25 (6.65-44.75)

< 0.001

All but High-Grade ADC or MEC

13/40

0.33 (0.18-0.47)

21.03 (7.39-59.87)

< 0.001

All but Male

8 /15

0.53 (0.28-0.79)

29.64 (7.09-123.98)

< 0.001

All but T3-4

19/30

0.63 (0.46-0.81)

49.65 (16.04-153.75)

< 0.001

23/33

0.70 (0.54-0.85)

79.16 (26.07-240.35)

< 0.001

One Factor Present

High-Grade ADC or MEC
Two Factors Present

Three Factors Present

All Four Factors Present
All

Odds ratios compare groups to the group with no factors present. ADC:
Adenocarcinoma. MEC: Mucoepidermoid carcinoma. N = 1805
As mentioned above, we also used maximum likelihood estimation to
accomplish multiple imputation of missing data to increase the power of our
regression and eliminate potential sources of bias. The results of this process are
found in Table 6. The same four factors included in the index are again shown to
be significant although to slightly different degrees.
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Table 5: Predictive Index of Lymph Node Involvement in Minor Salivary
Gland Cancer.

Variable

Predictive Index
Cases
Lymph
Proportion (95%
Node
Confidence
Positive
Interval)

Logistic Regression

Odds Ratio (95%
Confidence Interval)

P-Value

Number of Factors (v. 0)
0

9 /457

0.02 (0.01-0.03)

< 0.001

1

65/753

0.9 (0.07-0.11)

3.29 (1.56-6.93)

2

72/417

0.17 (0.14-0.21)

6.15 (2.91-13.04)

< 0.001

3

60/145

0.41 (0.33-0.49)

24.47 (10.96-54.61)

< 0.001

4

23/33

0.70 (0.54-0.85)

81.64 (26.71-249.54)

< 0.001

0.002

The logistic regression includes the covariate controls listed in Table 3. HosmerLemeshow statistic p-value is 0.133 indicating no difference between predicted
and observed values. NagelKerke R square is 0.464.
Multivariate logistic regressions were conducted to determine the factors
associated with a patient’s receiving a neck dissection or EBRT. Patients with
T2-T4 stage tumors were more likely to receive neck dissection than patients
with T1 stage tumors. Patients more likely to receive a neck dissection were
those with T2-T4 tumors, those with high-grade tumors, and those living in
Connecticut. Patients with tumors occurring in the sinuses/nasal cavity/middle
ear were less likely to receive neck dissection.
Forty-six percent of patients received EBRT. Patients who received
surgical neck dissection were also more likely to receive EBRT. Patients with
adenoid cystic carcinoma were more likely to receive EBRT, as were older
patients, those with T2-T4 stage, and those with high-grade tumors. Patients less
likely to receive EBRT were those with tumors occurring in the oral cavity, those
living in Los Angeles, and those diagnosed in the later years of the study.
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Table 6: Multivariate Logistic Regression of Clinicopathological Factors on
Regional Nodal Metastasis Using Imputed Data
Variable (Comparison Group for Categorical
variables)

Odds Ratio (95%
Confidence Interval)

P-Value

Histological Type and Grade
(v. Adenoid Cystic Carcinoma)
Acinic Cell Carcinoma

0.60 (0.13-2.65)

0.51

Mucoepidermoid Carcinoma, Low-Grade

1.14 (0.82-1.59)

0.43

Mucoepidermoid Carcinoma, High-Grade

3.79 (2.72-5.28)

< 0.001 ***

Adenocarcinoma, Low-Grade

1.21 (0.90-1.63)

0.21

Adenocarcinoma, High-Grade

4.10 (2.90-5.80)

< 0.001 ***

Miscellaneous

1.15 (0.56-2.38)

0.70

Pharynx Including Tonsil

3.05 (2.09-4.44)

< 0.001 ***

Nasal Cavity, Sinuses, and Middle Ear

0.54 (0.39-0.76)

< 0.001 ***

Larynx

1.84 (1.18-2.88)

0.01

T4 Stage (v. T1-3)

1.87 (1.42-2.47)

< 0.001 ***

Male Sex (v. Female)

1.57 (1.28-1.95)

< 0.001 ***

Tumor Size (mm)

1.00 (1.00-1.00)

0.65

Age

1.01 (1.00-1.01)

0.04 *

African American

1.09 (0.81-1.46)

0.58

Other

0.98 (0.60-1.60)

0.92

0.99 (0.97-1.00)

0.15

Primary Site (v. Mouth)

Race (v. Caucasian)

Controls
Year of Diagnosis

Finally, survival curves were generated to depict the relative survival of
patients with nodal metastasis versus those with no nodal metastasis (Figure 1).
For patients who were lymph node negative on presentation, the 5-, 10-, and 15year Kaplan-Meier overall survival (Standard Error in parentheses) was 78.4
(1.2), 61.3 (1.9), and 52.5 (2.4). For patients with lymph node involvement on
presentation, the 5-, 10-, and 15-year Kaplan-Meier overall survival was 42.4
(3.4), 25.7 (3.9), and 11.9 (5.0).
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Figure 1: Survival By Lymph Node Status.

The upper curve represents patients who were lymph node negative on
presentation and the lower curve represents patients with lymph node
involvement on presentation.

Discussion

Location of Minor Salivary Gland Malignancies and Distribution of
Histological Types
We present the largest population-based dataset on the distribution of
histological type by primary site to date. The oral cavity was the most common
site and the hard palate the most common sub-site. We report a larger proportion
of mucoepidermoid carcinoma than adenoid cystic carcinoma overall as opposed
to others’ findings that adenoid cystic carcinoma is the most common type.1, 3, 22
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Adenoid cystic carcinoma was the most prevalent sinonasal minor salivary gland
malignancy, mucoepidermoid was most prevalent in the oral cavity, and
adenocarcinomas were common in the pharynx and larynx.
The frequency at which certain histological types of minor salivary gland
cancers were diagnosed has changed over time. For example, polymorphous
low-grade adenocarcinomas were diagnosed only in the later years of the study
period from 2000-2004 and a total of 141 of these tumors were diagnosed during
that time. The separation of adenocarcinomas into low-and high-grade groups
should neutralize the absence of this diagnosis in the earlier years for the
purposes of our analysis. Mixed pleomorphic carcinoma is a diagnosis that has
come into usage only in the later years of the study.1 Only 11 cases were found
of this type.

Grade as a Predictive Factor of Lymph Node Metastasis
Grade was predictive of nodal metastasis for adenocarcinoma and
mucoepidermoid carcinoma but not for other histological types and sub-types.
There was no statistically significant difference in the rate of lymph node
metastasis between low and high-grade adenoid cystic carcinoma (ACC). Spiro
and colleagues have similarly found that dividing ACC by grade was unhelpful for
determining prognostic information for these tumors.3, 23 However, grade has
been found by some authors to be helpful in predicting survival in ACC.24, 25 It is
important to note that lymph node metastasis is generally considered less
important than local and distant control in ACC, and distant metastases occurs
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commonly even without neck nodal involvement in adenoid cystic carcinoma.24-27
All but one acinic cell carcinomas in this study were low-grade. Similarly, all
myoepithelial carcinomas were low-grade as were many adenocarcinoma subtypes. Other histological types for which grade was not a statistically significant
predictor of metastasis included mixed malignant tumor and pleomorphic
carcinoma. The sample size may be insufficient to detect an interaction between
grade and some histological sub-types including oxyphilic adenocarcinoma,
ductal carcinoma, and carcinosarcoma.

Race as a Potential Predictive Factor of Lymph Node Metastasis
Our results suggest that African American patients may be more likely to
present with nodal metastasis on univariate analysis. However, this was a trend
that did not achieve statistical significance. Also, this trend dissipated when
controlling for other factors on multivariate analysis. The factors controlled for
include markers of disease severity like T stage and grade. This suggests that
African American patients may be presenting with more advanced disease.
African American patients have been shown to have a higher incidence and
mortality regarding cancers of the oral cavity, pharynx and larynx than their white
counterparts.28, 29 In one study of oral and squamous cell carcinomas, African
American patients had decreased survival while controlling for stage and
treatment.30 Differences in mortality and survival across racial groups are also
more pronounced in men than in women.28

26
A Prognostic Index for Predicting Lymph Node Metastasis in Minor Salivary
Gland Cancer
While our reported rate of lymph node involvement of 16.0% is
approximately commensurate with other published studies, a large, in depth case
series may characterize the actual rate more accurately than SEER data.
However, because minor salivary gland cancers are relatively rare, a case series
this large may not be forthcoming in the immediate future.
Occult nodal metastasis for major salivary malignancies is between 12
and 20 percent.31-33 In a study of adenoid cystic carcinomas of the major and
minor salivary glands, Spiro and colleagues reported a rate of lymph node
involvement of 7.4% on initial presentation with an additional 7.0% developing
positive lymph nodes subsequently.34 Occult nodal metastasis in high-grade
adenocarcinoma was 40% in a small study by Sheahan and colleagues.35 They
found occult disease in two out of five necks dissected electively. High tumor
grade was also correlated with occult metastasis in a study by Rodriguez-Cuevas
and colleagues.15 In 36 elective neck dissections for major salivary gland
cancers, 50% of high-grade tumors had occult metastasis while no low-grade
tumors had occult metastasis. Because of limitations inherent to SEER data, it is
not possible to determine which node positive patients had clinically occult nodal
metastasis discovered in the operating room. However, our results have
implications for these patients. Because the data represent a wide range of
disease progression on presentation, patients who presented late with clinical
nodal metastasis but who would have been clinically metastasis free had they
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presented earlier are included. Three of the four factors found to be predictive of
nodal metastasis in our analysis are characteristics that do not change over the
progression of the malignancy such as histological type, primary site and gender.
Therefore, it is reasonable to think that clinically N0 patients presenting with
these factors are likely to go on and develop lymph node metastasis or already
have occult metastasis at presentation. Our results should be validated in a set of
patients with clinically N0 disease who also undergo neck dissection for
pathological staging.

Recommendations For Using The Index
While we do not assert that the percentages presented in the prognostic
index are directly predictive of occult nodal metastasis, we do recommend
consideration of the four factors listed when considering elective lymph node
treatment. We would advocate that patients with three or four of the four factors
should receive elective neck treatment. Patients with two of the factors should
also be strongly considered for elective neck treatment with neck dissection,
adjuvant radiation therapy, or both. It is also worth cautioning that even patients
with only one of the factors in the index may be appropriate candidates for
elective therapy, especially if the one factor is high-grade adenocarcinoma or
mucoepidermoid carcinoma. Because SEER data fails to capture neck relapses
in patients who were N0 for the first 4 months after diagnosis, figures hovering
around the cutoff range for elective treatment in the patients with one or two
factors may actually be appropriate candidates. On the other hand, if
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pretreatment staging with high resolution CT and ultrasound has failed to reveal
regional lymphadenopathy, and the clinician feels the risk of occult metastasis is
low, the model may also be used to identify patients who should have close
follow up for regional progression. As with any prognostic tool, this index will not
find complete applicability for each patient.
Elective neck dissection or radiation therapy treatment of the neck even in
high-risk patients may not convey local regional control or survival benefit.
However, Tran and colleagues reported that post-operative radiation therapy
improved local control in an analysis of 62 patients with minor salivary gland
cancer arising in the oral cavity.36 In a separate report, they found better
locoregional control with postoperative radiation therapy in 25 patients with minor
salivary gland cancers of the paranasal sinuses or nasal cavity.37 In a series of
256 minor salivary gland tumors in China, Chou and colleages showed that
patients with positive cervical metastasis found during neck dissection had higher
survival than those with no neck dissection.38 The methods employed were not
robust enough to establish the superiority of elective dissection in N0 patients
however.
It is interesting to note that increasing size of the primary tumor was
correlated with a patient receiving a neck dissection while it was not predictive of
nodal metastasis while controlling for other factors. In some sites such as the
sinuses and nasal cavity, tumors can attain large sizes before they present
clinically. In the case of the sinuses or nasal cavity, lymphatic involvement is less
likely. While T stage was found to be a significant factor predicting nodal
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metastasis, it is surprising that it did not eclipse other factors in the index as
might be expected.

Dealing With Missing Data
The SEER program has a standard rate of case ascertainment of 98%.39
However, staging and tumor grade information is often incomplete. Of 3926
patients identified with minor salivary gland tumors, lymph node metastasis was
only recorded for 2667. Furthermore, stage and grade information was not
recorded for many patients such that the dataset of patients with no missing data
pertinent to lymph node metastasis was only 1533. If these cases are not missing
at random, then our regression has the potential to be biased. Statistical analysis
indeed revealed some differences between the set of cases with fully recorded
grade and stage information versus the set of cases excluded because of
missing data. Cases with missing information tended to be in the earlier years of
the dataset, come from certain geographic registries, be of Caucasian race, have
high tumor grade, and have tumors in sites other than the mouth. Not
significantly different between the two sets were T stage, tumor size, gender,
age, and the use of external beam radiation therapy.
In general, we excluded cases with missing data from multivariate logistic
regression analysis. As a safeguard against the reduction in power and the
potential introduction of bias into our analysis, we used maximum likelihood
estimation to impute the missing data into our regression of clinicopathological
factors on lymph node involvement. This helped affirm the independent statistical
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significance of each of the variables included in the index. All four of these
variables were independently associated with lymph node metastasis to a pvalue of less than 0.001, although their respective odds ratios differed from our
main analysis. Older age was also found to be marginally significantly associated
with lymph node metastasis in this analysis. Again, this imputation was used only
as an exercise in testing the importance of missing variables in our construction
of the prognostic index. As indicated in the methods section, multiple imputation
was not used in constructing the index.

General Limitations of SEER Data
Besides occasional missing data regarding grade and stage, SEER has
some other important limitations that should be mentioned. One that is often cited
is the lack of margin status. This is a more important consideration in studies that
analyze the effects of various treatments on survival. For example, a study that
examines the effect of adjuvant radiation therapy on survival for head and neck
cancer must deal with the fact that patients with positive margins after surgery
are more likely to receive adjuvant radiation therapy but also have a poorer
prognosis. Other factors can be controlled for and one can exclude cases based
on the extent of surgery but marginal status will remain a confounding variable.
Another deficiency in SEER data is the lack of detail regarding the type,
dose, energy, and techniques of radiation used. This is a problem for the present
study only in our analysis of the clinicopathological characteristics associated
with the used of external beam radiation therapy. Many of the patients were likely
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treated only palliatively with lower doses and less extensive fields. Thus, they
were not in essence “selected” for treatment in the sense that we imply.

Choosing Target Volumes for Elective Treatment of the Neck: Skip
Metastasis
Beyond knowing that certain minor salivary gland cancers metastasize to
the neck, and that these patients might require elective treatment, the clinician
needs a basis for selecting a target volume in the neck. This section and the next
will present some current trends on treating two patterns of lymph node
metastasis: skip metastasis and contralateral metastasis to the neck.
A consensus on neck target selection guidelines for squamous cell
carcinomas of the head and neck was reached at the 43rd annual meeting of the
American Society of Therapeutic Radiology and Oncology in San Francisco,
November 2001. This consensus was reported by Eisbruch and colleagues in
2002 and applies only to patients with nodal stages N0 or N1.40 The guidelines
state that clinical involvement of levels II or III always calls for treatment of levels
Ib and IV ipsilaterally. Level V is always treated with ipsilateral involvement of
levels II-IV. Lateral T1-T2 floor of mouth tumors require treatment of ipsilateral
levels I-III and contralateral I-II. Ipsilateral level IV and contalateral level III are
added for tumors of higher T stage. Tongue tumors of tumor stage T1-T2 require
treatment of ipsilateral levels I-IV. More advanced T stages or tumors of the
anterior tongue require the same levels contralaterally. Finally, buccal mucosa
and retromolar trigone tumors require treatment of levels I-III ipsilaterally.
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Furthermore, it was suggested that extracapsular extension of any lymph node
calls for treatment of that neck level at a higher dose. For lateralized tumors of
any head and neck site, contralateral neck treatment should be added when the
N stage is greater than N1.
For neck stages N2 and greater, treatment of ipsilateral levels I-V has
been advocated in a consensus opinion published in 2006 by Gregoire and
others.41 They recommend that the retrostyloid space be included in this volume
if level II is involved, and that the supra-clavicular fossa be included if levels IV or
Vb are involved. These authors also repeat the recommendations of a consensus
opinion published in 2003 for the N0 or N1 patient.42 Specifically, they state that
in the N0 or N1 patient, when a positive lymph node abuts a muscle, or shows
radiological evidence of muscular infiltration, that the muscle should be included
in the CTV, at least within the level at which the invasion occurs and with 1 cm
margins. Also, they recommend that when an involved lymph node borders on
two adjacent levels, that both levels should be treated. Finally, for the postoperative patient, the abovementioned 2006 consensus recommendation was to
include the entire operative bed, especially in the case of extracapsular
extension. Then, for the post-operative patient, they repeat the recommendations
of including the retrostyloid space in case of level II involvement and the
supraclavicular fossa in case of level IV or Vb involvement, the inclusion of
invaded muscles, and the inclusion of adjacent levels when a pathologically
positive node borders on an undissected level.
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Deciding Target Volumes for Elective Treatment of the Neck: Contralateral
Lymph Node Involvement
Contralateral lymph node involvement (CLNI) is not common but presents
a challenge for the clinician who must decide whether to treat the contralateral
neck. Most published studies on CNLI report on squamous cell carcinomas
uniquely or include a small minority of minor salivary gland histologies. The
overall rate of CLNI on presentation is variable in published studies and ranges
from 3.0 to 9.2%.43-47 Longitudinal studies place the lifetime rate of CLNI for oral
cavity SCC from 9.4 to 17.3%.46, 48, 49
To consider some of the issues pertinent to determining which tumors
metastasize to the contralateral neck, it is useful to study the example of the oral
tongue cancer. Lymphatic metastasis from the tongue can follow different
patterns depending on the location of the primary tumor. It has been suggested
by Feind and others that more anterior tumors are at a higher risk for CLNI.45
They reported CLNI in 4 of 21 (19.0%) of tumors of the anterior 1/3 of the tongue
and in 3 of 80 (3.8%) of tumors of the middle 1/3 of the tongue. However, in the
former group, extension to the floor of mouth was noted in all patients with CLNI.
Tumors that involve the midline are known to be associated with higher
rates of CLNI. Increasing risk with further graded extension to and across the
midline was first reported in 1951 by Martin and others50 and more recently by
Kowalski and others.46, 50 Several papers have been published that attempt to
define other clinicopathological predictors of CLNI.45-48, 51, 52 However, a rational
basis for why factors such as T stage, histopatholigical grade and depth of
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invasion should cause lateralized tumors to metastasize to the contralateral neck
has generally been lacking. The crux of the rationale for CLNI is most likely
anatomical. Lymphatic capillaries and collecting trunks that cross the midline
exist and are utilized more frequently the more centrally located the primary
lesion.45 Vascular emobilization and perineural infiltration are two other factors
that provide an anatomically rational explanation for increased CLNI and they
were shown to correlate with CLNI by Kowalski and others.46 Gonzalez-Garcia
and others found that peritumoral inflammation correlated with CLNR.52 A
depressed immune response in this case may allow for more widespread
dissemination of metastases, including across the midline to the contralateral
neck.
Both early and relapse/failure CLNI are known to confer a poor prognosis
in oral cavity SCC. Gonzalez-Garcia and others reviewed 203 patients with SCC
of the lateral aspect of the tongue longitudinally and found cervical lymph node
relapse in 29 patients.52 Of those with relapse in the ipsilateral neck, 14 of 20
(70%) eventually died of the disease. Of those with relapse in the contralateral
neck 8 of 9 (89%) eventually died of the disease.
In the same study, relapse in the contralateral neck occurred only when
there was no contralateral neck dissection such as in 6 of 80 patients with (T2,
T3, T4) N0 tumors or tumors with cervical nodes less than 3 cm without
extracapsular extension. There were no cases of CLNR in 49 N0 or N1 patients
with lateral tumors that invaded midline of the tongue and who underwent
modified type III radical neck dissection. However, when considering all patients,
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the association between contralateral neck dissection and decreased CLNR was
not statistically significant. These data suggest that bilateral neck dissection was
at least effective in this small group of patients with tumors invading the midline.
In a study of stage I and II oral cavity SCC, Lim and others found only one
case of occult CLNI in 25 elective contralateral neck dissections in a total patient
sample of 54.53 Patients were followed for a mean of 56.3 months and no cases
of CLNR were found. All patients had unilateral lesions that did not extend across
the midline.
The type of elective contralateral neck dissection warranted may or may
not include Level IV. Woolgar and others showed that large mobile SCCs that
extend across the midline often exhibit an erratic pattern of CLNI and they
recommend neck dissection down to level IV bilaterally in these patients.47
Kowalski and others found that in 41 patients submitted to contralateral modified
radical neck dissection for oral cavity SCC, only once were nodes found in Level
IV.46 Twenty-four patients who did not receive elective contralateral neck
dissection had positive lymphatic involvement in Levels I-III, as did 19 of 79 who
submitted to a contralateral supraomohyoid neck dissection. Northrup and others
noted that CLNR occurred almost exclusively in the subdigastric area.49 PrinsBraam and others suggested that when contralateral nodes are found, they are
usually found at an anatomically higher level than positive ipsilateral nodes.54
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Adenoid Cystic Carcinoma: A Special Case
While most minor salivary gland tumors metastasize through the
lymphatics via then neck, one class, adenoid cystic carcinoma, is known to
commonly metastasize through perineural invasion as well.
ACC has been found more commonly in the minor salivary glands than in
the major salivary glands by some authors.27, 55 In a yet to be published report,
we found slightly more single-primary cases of ACC treated by definitive surgical
resection in the major salivary glands (1117) than in the minor salivary glands
(995) in population-based data. Of the major salivary glands, the parotid gland
and submandibular glands harbored the biggest share of cancers (567 and 471
respectively) and the oral cavity with its various sub-sites was most frequently
involved among minor salivary gland sites (618).
Buchholz and colleagues have had success treating adenoid cystic
carcinomas with fast neutron radiotherapy.56 They reported 5-year actuarial local
control and locoregional control rates of 76% and 63%, respectively. Eighty-one
percent (17/21) of patients treated with neutron therapy alone and 100% (13/13)
of the patients treated with neutron therapy and surgery achieved local control.

Conclusions
We present a population based survey of minor salivary gland malignancy
and an analysis of the predictors of lymph node metastasis. African Americans
with minor salivary gland cancer may present with more advanced disease.
Grade is a significant predictor of metastasis for adenocarcinoma and
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mucoepidermoid carcinoma but not for adenoid cystic carcinoma and other
subtypes. Tumor size is often considered in the decision to perform neck
dissection, yet it was not a significant predictor of nodal metastasis on
multivariate analysis. We present a prognostic index of lymph node involvement
for minor salivary gland cancer that uses the presence or absence of four
factors—male gender, pharyngeal primary site, T3 or T4 stage, and high-grade
adenocarcinoma or mucoepidermoid carcinoma. This index effectively
differentiates patients into risk groups for nodal metastasis.
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Table and Figure Legends
Table 1: Percentages in parentheses represent the percentage of cancers in the
site that are the histological type in question. Percentages in the bottom row
represent the percentage of the total found in that site.

Table 2: *Pearson Chi square test double-sided p-value. SE: Standard Error.
The T stage is unknown for 92 patients who had distant metastasis because
distant metastasis overrides tumor extension data in SEER coding. LN = Lymph
Node.

Table 3: 1533 patients are included in this analysis. The p-value is listed for the
odds ratio of each variable and for the Wald statistic for inclusion of complete
categorical variable groups. Cases with distant metastasis are excluded from this
analysis because T stage was not recorded/unknown when there was distant
metastasis. The Hosmer-Lemeshow test for this regression had a p-value of
0.023. The NagelKerke R Square is 0.526. ***p < 0.001. **0.001 < p <= 0.010.
*0.010 < p <= 0.050. †The number of lymph node positive cases is too small for
analysis.

Table 4: Odds ratios compare groups to the group with no factors present. ADC:
Adenocarcinoma. MEC: Mucoepidermoid carcinoma. N = 1805
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Table 5: N is the number of cases that fall in the group. The logistic regression
includes the covariate controls listed in Table 3. Hosmer-Lemeshow statistic pvalue is 0.133 indicating no difference between predicted and observed values.
NagelKerke R square is 0.464.

Figure 1: The blue curve represents patients who were lymph node negative on
presentation and the green curve represents patients with lymph node
involvement on presentation.

